Showing results (201-210 of 231) with videos related to

Sort By:
Pageof 24
Leukemia & Lymphoma|October 7, 2020
Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter studyMansi Bhurani, Lorenz Admojo, Carrie Van Der Weyden, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 27, 2020
Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple MyelomaAlexandra Gomez-Arteaga, Gunjan L Shah, Raymond E Baser, et al.
The Lancet. Oncology|October 16, 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trialThierry Facon, Shaji K Kumar, Torben Plesner, et al.
The New England Journal of Medicine|May 30, 2019
Daratumumab plus Lenalidomide and Dexamethasone for Untreated MyelomaThierry Facon, Shaji Kumar, Torben Plesner, et al.
Nature Medicine|August 15, 2023
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial resultsAlexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 9, 2020
Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATGJad Othman, Matthew Greenwood, John Moore, et al.
Blood Advances|May 5, 2026
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONENizar J Bahlis, Thierry Facon, Jesús F San-Miguel, et al.
The New England Journal of Medicine|December 8, 2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A Burger, Alessandra Tedeschi, Paul M Barr, et al.
The New England Journal of Medicine|August 30, 2023
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple MyelomaPaul G Richardson, Suzanne Trudel, Rakesh Popat, et al.
Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Pageof 24